13/02/2015 - 17:23 The Food and Drug Administration has approved the kinase inhibitor lenvatinib (Lenvima) for the treatment of differentiated thyroid cancer, the agency... More » Visit websiteField of Interest: OncologyCategories: CEN || FDA & CDCCEN || NewsONCR || FDA & CDCONCR || NewsONCR || Head & NeckFPN || FDA & CDCFPN || NewsNews Feed: Internal Medicine News - Oncology
